{"id":"cyclophosphamide-prednisone-lenalidomide","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Neuropathy"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hemorrhagic cystitis"},{"rate":null,"effect":"Thromboembolism"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:07:27.062743","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclophosphamide is an alkylating agent that damages DNA in rapidly dividing cells; prednisone is a corticosteroid that suppresses immune responses; lenalidomide is an IMiD that binds cereblon, enhancing immune cell activation while inhibiting angiogenesis and promoting apoptosis in malignant cells. Together, this triplet combination leverages chemotherapy, immunosuppression, and immunomodulation for treating hematologic malignancies.","oneSentence":"This combination uses cyclophosphamide and prednisone as immunosuppressive/chemotherapy agents alongside lenalidomide, an immunomodulatory drug that enhances T-cell proliferation and has anti-angiogenic properties.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:24.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (likely indication based on typical use of this triplet)"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT06803693","phase":"PHASE2","title":"Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":152},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":"Follicular Lymphoma","enrollment":400},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":62},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT07081022","phase":"PHASE2","title":"JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-08-17","conditions":"B-cell Non-Hodgkin's Lymphoma","enrollment":180},{"nctId":"NCT05279300","phase":"PHASE1","title":"A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2022-03-28","conditions":"Advanced Solid Tumor, Advanced Lymphoma","enrollment":480},{"nctId":"NCT02911142","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-03","conditions":"Primary Effusion Lymphoma, B-Cell Neoplasm","enrollment":17},{"nctId":"NCT01865110","phase":"PHASE3","title":"R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2013-11","conditions":"Mantle Cell Lymphoma","enrollment":623},{"nctId":"NCT00670358","phase":"PHASE1, PHASE2","title":"Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-08-25","conditions":"Lymphoma","enrollment":138},{"nctId":"NCT05201248","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-03-10","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":49},{"nctId":"NCT06674096","phase":"PHASE2","title":"RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-11-06","conditions":"Double-expressor Lymphoma","enrollment":44},{"nctId":"NCT01093196","phase":"PHASE3","title":"Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2009-10","conditions":"Multiple Myeloma","enrollment":660},{"nctId":"NCT06284122","phase":"PHASE3","title":"Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2024-06-07","conditions":"Follicular Lymphoma","enrollment":790},{"nctId":"NCT04974216","phase":"PHASE2","title":"Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-12-20","conditions":"DLBCL","enrollment":71},{"nctId":"NCT02529852","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-11-04","conditions":"Lymphoma","enrollment":59},{"nctId":"NCT02633137","phase":"PHASE2","title":"Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-12-14","conditions":"Mantle Cell Lymphoma, Untreated","enrollment":49},{"nctId":"NCT06516978","phase":"PHASE2","title":"A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":528},{"nctId":"NCT06441097","phase":"PHASE2","title":"Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":152},{"nctId":"NCT04164368","phase":"PHASE2","title":"Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Fudan University","startDate":"2019-10-22","conditions":"Double Expressor Lymphoma","enrollment":67},{"nctId":"NCT02636322","phase":"PHASE2","title":"Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-03-29","conditions":"Diffuse Large B-Cell Lymphoma Unclassifiable","enrollment":60},{"nctId":"NCT06212596","phase":"PHASE2","title":"Selinexor, Cyclophosphamide and Prednisone in Myeloma","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2018-07-16","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":66},{"nctId":"NCT02561273","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-09-28","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma","enrollment":54},{"nctId":"NCT05848765","phase":"PHASE2","title":"Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2023-09-04","conditions":"Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":284},{"nctId":"NCT02188368","phase":"PHASE2","title":"Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-07-07","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT05290090","phase":"PHASE2","title":"ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":31},{"nctId":"NCT01166113","phase":"PHASE1, PHASE2","title":"Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT02285062","phase":"PHASE3","title":"Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-02-17","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":570},{"nctId":"NCT04480099","phase":"PHASE2","title":"Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-07-29","conditions":"Peripheral T-cell Lymphoma","enrollment":96},{"nctId":"NCT05899621","phase":"","title":"A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-06-01","conditions":"Follicular Lymphoma","enrollment":332},{"nctId":"NCT05179733","phase":"PHASE3","title":"The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-03-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":280},{"nctId":"NCT03003520","phase":"PHASE2","title":"A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-02-28","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":46},{"nctId":"NCT05351346","phase":"PHASE3","title":"Genotype-guided Treatment in DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-06-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":1100},{"nctId":"NCT04922567","phase":"PHASE2","title":"Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-04-01","conditions":"Peripheral T-Cell Lymphoma, Lenalidomide, CHOP","enrollment":289},{"nctId":"NCT05428670","phase":"PHASE2","title":"The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2022-06-15","conditions":"Diffuse Large B Cell Lymphoma","enrollment":150},{"nctId":"NCT05200312","phase":"PHASE2","title":"A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-02-01","conditions":"Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT04842487","phase":"PHASE2","title":"R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-04-10","conditions":"DLBCL","enrollment":80},{"nctId":"NCT04842318","phase":"PHASE4","title":"Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-03-01","conditions":"Follicular Lymphoma","enrollment":789},{"nctId":"NCT02128061","phase":"PHASE3","title":"Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2014-08","conditions":"Diffuse Large B Cell Lymphoma","enrollment":250},{"nctId":"NCT04025593","phase":"PHASE2","title":"Biomarker Guided Treatment in DLBCL","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2019-07-17","conditions":"Diffuse Large B Cell Lymphoma","enrollment":128},{"nctId":"NCT04544059","phase":"PHASE2","title":"Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2020-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":87},{"nctId":"NCT04432714","phase":"PHASE1, PHASE2","title":"Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-06-09","conditions":"DLBCL, Untreated, MYC Gene Rearrangement","enrollment":81},{"nctId":"NCT04152577","phase":"PHASE4","title":"R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2019-06-05","conditions":"Lymphoma, B-Cell","enrollment":200},{"nctId":"NCT03715296","phase":"","title":"Lenalidomide Based Immunotherapy in the Treatment of DLBCL","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2018-10-18","conditions":"Diffuse Large B Cell Lymphoma","enrollment":200},{"nctId":"NCT02142049","phase":"PHASE1, PHASE2","title":"Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2014-05","conditions":"Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory","enrollment":35},{"nctId":"NCT00540644","phase":"PHASE2","title":"Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Attaya Suvannasankha","startDate":"2007-10","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT01352338","phase":"PHASE1, PHASE2","title":"Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2011-08","conditions":"Multiple Myeloma","enrollment":82},{"nctId":"NCT00907348","phase":"PHASE2","title":"Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2007-10","conditions":"Non Hodgkin Lymphoma, Follicular Lymphoma","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2020 Jul","pmid":"31582542","title":"Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.","journal":"Haematologica"},{"date":"2016 Mar 3","pmid":"26729895","title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.","journal":"Blood"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cyclophosphamide, Prednisone, Lenalidomide","genericName":"Cyclophosphamide, Prednisone, Lenalidomide","companyName":"Fondazione EMN Italy Onlus","companyId":"fondazione-emn-italy-onlus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses cyclophosphamide and prednisone as immunosuppressive/chemotherapy agents alongside lenalidomide, an immunomodulatory drug that enhances T-cell proliferation and has anti-angiogenic properties. Used for Multiple myeloma (likely indication based on typical use of this triplet).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}